Imaging Key Biomarkers of Tumor Angiogenesis
Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling | BMC Cancer | Full Text
Mouse models for studying angiogenesis and lymphangiogenesis in cancer - ScienceDirect
Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity | Experimental & Molecular Medicine
Tumor angiogenesis: causes, consequences, challenges and opportunities | SpringerLink
Anti-angiogenic effects of VEGF stimulation on endothelium deficient in phosphoinositide recycling | Nature Communications
3D Microfluidic Platform and Tumor Vascular Mapping for Evaluating Anti- Angiogenic RNAi-Based Nanomedicine | ACS Nano
Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis: Cell
Apelin inhibition prevents resistance and metastasis associated with anti‐ angiogenic therapy | EMBO Molecular Medicine
Antiangiogenic therapy: Markers of response, "normalization" and resistance. | Semantic Scholar
Relapse of pathological angiogenesis: functional role of the basement membrane and potential treatment strategies | Experimental & Molecular Medicine
Tumor Angiogenesis | NEJM
Angiogenesis in Cancer: Novus Biologicals
Reconciling the distinct roles of angiogenic/anti-angiogenic factors in the placenta and maternal circulation of normal and pathological pregnancies | SpringerLink
Frontiers | Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies
Tumor angiogenesis: molecular pathways and therapeutic targets | Nature Medicine
Angiogenic Factors in Preeclampsia | Hypertension
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa | Nature Reviews Clinical Oncology
Anti-angiogenic biomarkers | Phase I Biomarker Laboratory
Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders - ScienceDirect
Imaging Key Biomarkers of Tumor Angiogenesis
Cells | Free Full-Text | Trends and Challenges in Tumor Anti-Angiogenic Therapies
